Table 1 Patients’ characteristics of four centres
Characteristic | CHUM | CHUS | HGJ | HMR | p |
|---|---|---|---|---|---|
64 | 75 | 55 | 26 | ||
Sexa | Â | Â | Â | Â | 0.715 |
Male | 48 (75%) | 55 (73.3%) | 45 (81.8%) | 20 (76.9%) | Â |
Female | 16 (25%) | 20 (26.7%) | 10 (18.2%) | 6 (23.1%) | Â |
Ageb (mean (SD)) | 63.41 (9.26) | 64.04 (10.78) | 62.53 (10.03) | 66.46 (9.01) | 0.411 |
Primary Site c |  |  |  |  | < 0.001 |
Nasopharynx | 1 (1.6%) | 5 (6.7%) | 6 (10.9%) | 6 (23.1%) | Â |
Oropharynx | 57 (89.1%) | 56 (74.7%) | 36 (65.5%) | 11 (42.3%) | Â |
Hypopharynx | 1 (1.6%) | 1 (1.3%) | 3 (5.5%) | 6 (23.1%) | Â |
Larynx | 0 (0.0%) | 13 (17.3%) | 8 (14.5%) | 3 (11.5%) | Â |
Unknown | 5 (7.8%) | 0 (0.0%) | 2 (3.6%) | 0 (0.0%) | Â |
T-stagec | Â | Â | Â | Â | 0.016 |
Tx | 5 (7.8%) | 0 (0.0%) | 2 (3.6%) | 1 (3.8%) | Â |
T1 | 8 (12.5%) | 6 (8.0%) | 11 (20.0%) | 2 (7.7%) | Â |
T2 | 28 (43.8%) | 32 (42.7%) | 14 (25.5%) | 9 (34.6%) | Â |
T3 | 8 (28.1%) | 23 (30.7%) | 23 (41.8%) | 6 (23.1%) | Â |
T4 | 5 (7.8%) | 14 (18.7%) | 5 (9.1%) | 8 (30.8%) | Â |
N-stagec | Â | Â | Â | Â | 0.001 |
N0 | 4 (6.2%) | 24 (32.0%) | 11 (20.0%) | 3 (11.5%) | Â |
N1 | 8 (12.5%) | 7 (9.3%) | 12 (21.8%) | 3 (11.5%) | Â |
N2 | 45 (70.3%) | 41 (54.7%) | 31 (56.4%) | 15 (57.7%) | Â |
N3 | 7 (10.9%) | 3 (4.0%) | 1 (1.8%) | 5 (19.2%) | Â |
Stagec | Â | Â | Â | Â | 0.002 |
Stage I | 0 (0.0%) | 1 (1.3%) | 1 (1.8%) | 0 (0.0%) | Â |
Stage II | 2 (3.1%) | 11 (14.7%) | 3 (5.5%) | 3 (11.5%) | Â |
Stage III | 7 (10.9%) | 13 (17.3%) | 21 (38.2%) | 2 (7.7%) | Â |
Stage IV | 53 (82.8%) | 50 (66.7%) | 30 (54.5%) | 21 (80.8%) | Â |
Unknown | 2 (3.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | Â |
Therapyc |  |  |  |  | < 0.001 |
RT | 4 (6.2%) | 21(28.0%) | 3(5.5%) | 5(19.2%) | Â |
CRT | 60 (93.8%) | 54 (72.0%) | 52 (94.5%) | 21 (80.8%) | Â |
Deatha |  |  |  |  | < 0.001 |
Yes | 4(6.2%) | 12(16.0%) | 6(10.9%) | 15(57.7%) | Â |
No | 60 (93.8%) | 63 (84.0%) | 49 (89.1%) | 11 (42.3%) | Â |